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Cigarette smoking has been causally linked several diseases, primarily lung cancer and chronic
obstructive lung disease (COPD). The diagnosis of COPD currently involves an assessment of
smoking and/or occupational exposures, a history of cough, sputum and dyspnea and spiro-
metric measures of airflow obstruction and since spirometric measures take long follow up
times to detect significant changes, surrogate measures of outcome capable of predicting
long-term health changes have been sought for. These include biomarkers of oxidative stress,
inflammation and tissue damage in sputum, bronchoalveolar lavage, exhaled breath and
serum. Published biomarker studies have not always accurately compared patients with COPD
with age-matched cigarette smokers and non-smoking normal subjects without significant
airflow limitation, also comparable for other exposures. Consequently, the interpretation of
biomarker association studies is somewhat difficult. The purpose of this narrative review is
to summarize publications reporting cellular, soluble or volatile marker of obstructive lung
disease in populations of healthy non-smokers and healthy smokers, in order to determine
whether the biomarkers examined could be specifically associated with exposure to tobacco
smoke rather than with inflammation and airway hyper-reactivity. As induced sputum has been
the most widely used investigative tool, this review has been aimed at assessing induced
sputum biomarkers, referring to lung biopsy, bronchoalveolar lavage and exhaled breath
markers as supporting evidence for biomarkers associations identified with induced sputum
studies.
ª 2009 Elsevier Ltd. All rights reserved.39 06 20902788.
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The use of tobacco, especially cigarette smoking, has been
causally linked to several diseases, primarily lung cancer,
chronic obstructive lung disease (COPD), and coronary artery
disease. The 1964 and the 1989 United States Surgeon Gen-
eral’s reports pointed to a hundred-fold increase in lung
cancer during the past century and to the alarming increase
in chronic bronchitis and emphysema deaths.1e3 In the 40
year follow up analysis of the British doctors study of Doll and
Colleagues about 15% of current cigarette smokers died of
lung cancer, with a 17.4-fold increased risk of mortality risk,
and 10% died of chronic bronchitis and emphysema, with
a 9.9-fold increase in risk, compared to non-smokers.4
In fact, over thepast forty yearsCOPDhasbecomea leading
cause of morbidity and mortality worldwide. Currently, COPD
is the fourth-leading cause of death in the USA and Europe,5
with mortality more than doubled in females over the past 20
yrs.6However, COPDprevalenceandmorbidity is thought tobe
greatly underestimated as the disease is usually not diagnosed
until clinically apparent and moderately advanced. Out of the
6.8% of the general USA population which was found to have
low pulmonary function in the National Health and Nutrition
Examination Survey (NHANES) study, a striking 63% of those
withmildly low pulmonary function (forced expiratory volume
in one second (FEV-1) <80% predicted) and 44% of those with
moderately to severely impaired pulmonary function
(FEV-1< 50% predicted) did not have yet a diagnosis of
obstructive lung disease.7
Current diagnosis of COPD involves an assessment of
smoking and/or occupational exposures, a history of cough,
sputum and dyspnea and a measure of airflow obstruction.
As spirometry is the only widely available tool to identify and
monitor airflow obstruction, the diagnosis and the staging of
COPD are largely based on FEV1 measures.
5 The usefulness of
FEV1 measures for diagnosis of COPD and for the evaluation
of treatment effects has been proven in major studies con-
ducted over the past 30 years.8,9 However, as spirometric
measures do require long follow up periods to determine
whether interventions tested in clinical trials determine
clinically relevant changes in patient status, surrogate
outcome measures capable of predicting long-term
responses are been intensely sought for. A recent systematic
review by Franciosi and Colleagues on surrogate outcome
measures, including a number of biomarkers, has shown that
endpoints commonly used to define patient clinical status
and to quantify treatment effects had relatively poor
sensitivity.10 Published studies examined by Franciosi and
Colleagues in this review reported sufficient data for the
systematic analysis of interleukin (IL)-6 and IL-8, tumor
necrosis factor-alpha (TNF-a), fibrinogen, C-reactive protein
(CRP), nitric oxide (NO) and carbon monoxide (CO) studies of
marker levels in serum, sputum, bronchoalveolar lavage(BAL) and exhaled breath. With regard to serum measures,
no sufficient data were available for the systematic review
of IL-6 and IL-8, while the TNF-a data demonstrated a trend
toward an association of TNF-a levels and COPD severity,
although no statistically significant differences could be
demonstrated in the comparison between healthy subjects
and COPD patients. The same Authors did not find sufficient
data for the meta-analysis of induced sputum data on TNF-a,
IL-6, fibrinogen and CRP, although they found a significant
difference in the levels of IL-8 of mild COPD patients
compared to moderate COPD.10 The data available in the
literature on the levels of IL-6, IL-8, TNF-a, fibrinogen and
CRP in BAL were also scarce and only BAL IL-8 levels were
found to be different in healthy subjects in comparison to
patients in mild COPD stages. Finally, these meta-analyses
revealed no obvious relationship between COPD severity and
either NO and CO levels in exhaled breath. Collectively, the
results of this systematic review may suggest that longitu-
dinal studies and disease modelling should be the primary
methods for assessing whether potential markers of disease
progression for use in COPD diagnosis and clinical trials.10
More recently, the potential role of respiratory
biomarkers as surrogate outcome measures in COPD phar-
macological trials was the object of a section of a recent
statement of an American Thoracic Society (ATS)/European
Respiratory Society (ERS) Task Force on outcomes of
COPD,11 where Barnes and Page described a number of
markers identified in tissue biopsies, BAL, induced sputum
and exhaled breath. Infiltrating, activated CD8þ T
lymphocytes expressing interferon-gamma (IFN-g), induc-
ible protein-10 and IL-9, as well as chemokine receptors
associated to a type-1 response, such as CXC chemokine
receptor 3 (CXCR3) have been identified in tissue biopsies
and appear to characterize the local immune response of
COPD patients. In addition, airway eosinophila and neu-
trophila associated with up regulation of RANTES (regulated
upon activation, normal T cell expressed and secreted) and
the CX chemokine ligand 5 (CXCL5) appear to character
acute COPD exacerbation.12e14 In addition, the numbers of
eosinophils and the levels of leukocyte mediators such as
eosinophil cationic protein (ECP), myeloperoxidase (MPO)
and IL-8, have been found to be elevated in COPD patients
compared to healthy non-smokers, although the levels of
cellular and soluble markers were not statistically different
from those found in healthy smokers. Interestingly, tryp-
tase and histamine levels have been indicated as COPD
markers, although no healthy smoker studies have been
performed which could help with discriminating tobacco
smoke effects form to COPD-associated inflammation.15,16
Overall, the increase in the numbers of inflammatory cells,
most prominently neutrophils and, in some patients,
eosinophils, together with the increase in the levels of
some soluble mediators including, chiefly IL-8, have been
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Similarly, hydrogen peroxide (H2O2) and 8-Isoprostane have
been identified as the biomarkers of inflammation in COPD
in exhaled breath condensate (EBC).20,21
Interestingly, in response to the question addressed by
this ATS/ERS statement of whether COPD biomarkers can
predict the response to therapeutic interventions, only
mast cell numbers, but not the numbers of macrophages,
lymphocytes and neutrophils in tissue biopsies, appear to
respond to corticosteroid treatment, while the number of
neutrophils and lymphocytes in the BAL have been shown to
respond to inhaled corticosteroid treatment, although no
long-term studies in large populations have been performed
to corroborate these data.11
Since in published COPD biomarkers studies affected
subjects have not always been compared with age-matched
cigarette smoking and non-smoking controls, thus making
the interpretation of biomarker associations somewhat
difficult, this narrative review has been designed to explore
determine whether the biomarkers examined in COPD
studies could be associated with exposure to tobacco
smoke rather than with inflammation and airway hyper-
reactivity. To this end, this review summarizes lung
biomarker studies investigating cellular, soluble or volatile
biomarkers of obstructive lung disease in populations of
healthy non-smoking and smoking subjects.
COPD biomarker studies were searched on Medline using
biomarker, tobacco and smoke in addition to lung, respi-
ratory, induced sputum, BAL and exhaled breath as key
words. Papers including disease groups, such as asthma,
COPD or cancer and control population characterized for
smoking history were examined. Biomarker studies included
induced sputum studies as well as BAL, tissue biopsy, EBC
studies. As induced sputum has been validated as
a sampling procedure for the evaluation of the airway both
for research and clinical purposes, this review was focused
upon induced sputum studies, using biopsy, BAL and EBC
studies as comparators for marker validation. Animal
studies were described wherever they might have been of
importance to support the role of a gene/molecule in the
pathogenesis of tobacco smoke-associated disease.
Sampling procedures
Over the past thirty years, a variety of sampling procedures
have been developed to gauge lung damage and inflam-
mation in disease states, including fiberoptic bronchoscopy
(FOB) with BAL, exhaled breath analysis, EBC and sputum
induction, in addition to the collection of blood and urine
samples.
FOB with BAL was introduced in mid 1970s22 to explore
the lower respiratory tract (LRT) in a variety of lung
disorders,23 including cigarette-induced disorders like
emphysema.24 BAL is a relatively benign procedure and
local adverse reactions are minor, with pulmonary infiltra-
tion and transient decrease in pulmonary function rarely
observed.25 It has been widely used as a diagnostic and
research tool to study interstitial lung disorders such as
sarcoidosis,26 pulmonary fibrosis,27 occupational lung
disorders such as silicosis and coal worker pneumoconiosis,
asbestosis,28 berylliosis and hypersensitivity pneumonitis,
smoke-induced lung disorders such COPD and hereditaryemphysema,24 hystiocytosis-X28 and lung cancer,29 as well
as to investigate basic lung mucosal immunology.30 The ERS
and the ATS have issued guidelines to standardize the
procedure.25,31
Exhaled breath analysis allows the measure of volatile
mediators, such as NO,32 CO,33e35 ethane and pentane,36e38
in addition to nonvolatile substances in the liquid phase of
exhalate such as H2O2.
20,39e41 The ATS/ERS guidelines
recommend the measurement of exhaled mediators as
ideally suited for the serial monitoring of patients with
airways disorders.42
EBC collection is a non-invasive sampling procedure of
lower respiratory examination that has allowed the analysis
of a variety of factors including ammonia, H2O2, NO, iso-
prostanes, leukotrienes, adenosine, peptides and cyto-
kines.43 This technique has been widely used in airways
research and the ATS and the ERS jointly sponsored guide-
lines for EBC analysis.43
Blood and urine samples have been also used to identify
COPD-associated alterations, suggesting that cigarette
smoke may induce systemic inflammatory responses and
indicating that such samples may be suitable to screen for
markers of smoke-related abnormalities, including oxida-
tive stress and genotoxic damage.44
Sputum induction
Sputum induction is a non-invasive, safe and repeatable
procedure which has been developed for examining healthy
and diseased subjects.45
Sputum induction consists of inhaling an aerosol of saline
solution over a determined time-period and to produce
timed, forced expectoration efforts.46 It requires a high
degree of cooperation from the patient and it is advisable
that the procedure is performed in a quiet environment,
separate from other routine activities. Sputum induction
should be performed by adequately trained technologists,
or nurses with sufficient experience in the procedure,
under the supervision of an experienced physician. Resus-
citation equipment should be available, as recommended
for other specific and non-specific bronchial challenge
procedures,47 and the supervising physician should be in the
vicinity at all times during sputum induction in order to
intervene immediately in the event of any adverse reac-
tion. The patient must be clearly informed prior to the
procedure and informed consent obtained.46
The ERS Guidelines recommend that, as hypertonic
saline may cause bronchial constriction in asthmatic
subjects, short-acting b2-agonist bronchodilator pre-treat-
ment should be given to prevent excessive bronchospasm,47
and the pre-treatment of choice has generally been sal-
butamol, at the dosage of 200 mcg, i.e. 2 puffs, to 400 mcg
i.e., 4 puffs, from a standard metered-dose inhaler.47
Monitoring pulmonary function during sputum induction is
necessary for safety reasons, in order to assess excessive
bronchoconstriction. FEV1 should be measured pre-bron-
chodilator, post-bronchodilator and it should be monitored
at intervals of 5 min during aerosol inhalation. Induction
should be terminated if a fall in FEV1 of >20% compared
with the post-bronchodilator value or if symptoms occur.47
At the end of the induction procedure, patients should be
given an inhaled short-acting b2-agonist, particularly if
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value. Patients should remain in the laboratory and be
monitored until their FEV1 or peak expiratory flow has
returned to within 5% of the baseline value.46
The concentration of saline used for sputum induction has
ranged from 0.9 to 7% in different studies and some investi-
gators change concentration during the procedure, starting
with 3% and subsequently increasing to 4 and 5%. Little is
known about the effect of different saline concentrations on
the levels of soluble mediators in induced sputum; however,
a study has shown no difference in ECP in the supernatant of
sputum induced using either isotonic or hypertonic solu-
tion.47 Theconsensus is therefore that a 4.5% sodiumchloride
solution, which is commercially available, effective and
generally well tolerated, should be used as standard.
The typeandoutput of thenebulizer are also important and
ultrasonic nebulizers are recommended since other nebulizers
do not usually exhibit sufficient output of saline aerosol, and
there is consensus that an ultrasonic nebulizer should be used
with an output of 1 mlmin1. However, the influence of
different nebulizer set-ups (length of tubing, valve, etc.) has
not been systematically evaluated.47
The duration of inhalation is an important variable, as
some studies have reported that the cellular and
biochemical constituents of induced sputum change during
the course of sputum induction, showing that neutrophils
and eosinophils dominate earlier samples whereas
lymphocyte and macrophage counts are increased in the
later samples, suggesting that different compartments of
the respiratory tract are sampled at different procedure
times.48 Induction procedures have been proposed to last
15e30 min, and 20 min is the time length recommended by
the ERS panel.47 The subject may be asked to stop inhala-
tion in order to cough up sputum after 5, 10, 15 and 20 min
of induction or whenever he/she feels the urge to do so.47
In patients with asthma or COPD sputum is spontane-
ously produced; in these subjects, spontaneously produced
sputum contains percentages of inflammatory cells and
mediators similar to those in induced sputum. It is recom-
mended to process sputum as soon as possible, within 2 h
from induction, in order to ensure optimum cell counting
and staining.49,50 Complete homogenization is also impor-
tant and can be achieved by the use of dithiothreitol (DTT)
and dithioerythritol (DTE) to break the disulphide bonds in
mucin molecules, allowing cells to be released.50 After
incubation in a shaking water bath at 37 C or a tube rocker
at 22 C for 15 min,50 the sample is filtered by most inves-
tigators through a 48-mcm nylon mesh to remove mucus
and debris50 and total cell count is performed manually by
using a haemocytometer while determining cell viability by
the trypan blue exclusion method.50,51
Cell analysis is usually carried out using either smears or
cytopreparations. Preparation of cytospins with an
optimum number of cells is felt to provide a more accurate
estimate of cell distribution than smears.50,52 Cytochemical
and immunocytochemical methods can be used to identify
and quantify inflammatory cell populations and sub-pop-
ulations in the sputum cellular phase. Flow cytometry has
been applied to sputum analysis.53
With the caveat that different sputum induction proto-
cols might generate inter-laboratory inconsistent results,
fluid-phase mediators can be measured with highreproducibility in induced sputum with a variety of immu-
noassays performed to measure solutes, as cytokines,54e56
and normal reference ranges derived from relatively large
adult populations have been published.57
Soluble markers of tobacco smoke-induced
lung damage
Chemokines and chemokine receptors
Chemokines are low-molecular weight polypeptides involved
in the migration of inflammatory cells and their receptors are
thought to direct T-lymphocyte homing to the lung respiratory
tract. Chemokines are classified into CXC, CC and C subfam-
ilies according to amino acid motifs present in their
sequences. They include the growth-related oncogene-alpha
(GRO-a), monocyte chemotactic protein-1 (MCP-1) and IL-8,
which are produced by a variety of immune and non-immune
cells and whose secretion is induced by pro-inflammatory
cytokines, viruses, bacterial products, the complement frac-
tion (C)5a and leukotriene B4 (LTB4).18,58,59 Chemokine
receptors identify Th1/Th2 T-cell phenotypes: Th-1 type cells
preferentially express CXCR3 and CC chemokine receptor 5
(CCR5)while Th-2 type cells express CC chemokine receptor 3
(CCR3), CC chemokine receptor 4 (CCR4) and CC chemokine
receptor 8 (CCR8).
Several studies on lung tissue biopsies and BAL have shown
that chemokine genes are activated in COPD and in tobacco
smokers. Tomaki and Coworkers have shown elevated gene
expression of MCP-1, GRO-a and IL-8 in COPD.60 De Boer et al.
have foundthatMCP-1wasexpressedbymacrophages,Tcells,
endothelial and epithelial cells in lung biopsies of control
individuals and smokers with COPD. In particular, MCP-1 was
expressed at higher levels in the bronchioles of smokers with
COPD whereby it correlated with the numbers of intra-
epithelial macrophages, suggesting that MCP-1 may be
involved in the recruitment of macrophages into the airway
epithelium in COPD.61 Interestingly, mRNA expression of MCP-
1 in bronchial epithelial cells of patients with COPD has been
found to be higher compared to never smokers or smokers
without either airflow limitation or emphysema, suggesting
a role of the bronchiolar epithelium as the source of pro-
inflammatory chemokines in COPD.62 Similarly, Schulz et al
(2004) showed that IL-8 and GRO-a genes were expressed at
higher levels by cultured bronchiolar epithelial cells from
COPD-affected subjects compared to healthy smokers.63
BAL studies have, on the other hand, indicated that
chemokine genes are activated in healthy smokers. In the
BAL study by Capelli and Colleagues, MCP-1 levels were
higher in patients with COPD and healthy smokers than in
non-smokers,64 suggesting that increased MCP-1 may be
related to smoking and may be causative of the smoker’s
lung inflammatory reaction. Similarly, Kuschner and
Coworkers found elevated IL-8 levels in smokers, compared
with non-smokers; interestingly, IL-8 elevation was ciga-
rette exposure-dependent.65 Schulz (2003) also reported
that constitutive and stimulated IL-8 gene expression in
cultured bronchial epithelial cells from COPD subjects was
significantly higher than in healthy smokers and control
subjects, whereas no differences were seen between
smokers and controls 66,67
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Studies on induced sputum have shown that both GRO-a and
MCP-1 levels are significantly increased in smokers with
COPD (31 11 and 0.8 0.4 ng/ml, respectively) in
comparison with non-smokers (2 2 and 0.2 0.1 ng/ml,
respectively) and healthy smokers (3.0 0.8 and
0.1 0.04 ng/ml, respectively). A positive correlation was
found between chemokine levels and the numbers of
neutrophils for both GRO-a and MCP-1 (rZ 0.6, p< 0.001;
rZ 0.4, p< 0.01, respectively).68
With regard to IL-8, Gelder and Colleagues have found
that induced sputum cells expressed the IL-8 gene in 50% of
normal non-smoking subjects.69 In the study of Rovina and
Colleagues, IL-8 concentrations in induced sputum were
increased in COPD patients (5.6 ng/ml [2.3e10]) in
comparison with asymptomatic smokers (1.27 ng/ml (0.72e
3.2), pZ 0.021), which were not different from non-
smokers (0.73 ng/ml (0.6e1.4), pZ 0.000, compared to
COPD).70 Yamamoto et al. also found that IL-8 expression
was increased in induced sputum of patients with COPD in
comparison to healthy control subjects (21.0 1.8 vs.
3.3 0.7, p< 0.0001)18 (Table 1). In this study, IL-8 sputum
levels were correlated with the degree of airflow obstruc-
tion (rZ0.78 with FEV1/FVC, p< 0.0001). Collectively,
and in contrast with biopsy and BAL data indicating an
inciting role of tobacco smoke exposure upon heightened
chemokine expression in the lung of tobacco smokers [63e
69], the GRO-a, MCP-1 and IL-8 induced sputum data
suggest that increased chemokine levels in sputum are
related to lung inflammation, possibly with the inflamma-
tion of COPD, and not just with cigarette smoke exposure.
In addition, in the study of Costa et al., sputum levels of
CX chemokine ligand 9 (CXCL9), CX chemokine ligand 10
(CXCL10), CX chemokine ligand 11 (CXCL11), and C che-
mokine ligand 5 (CCL5) were significantly increased in the
sputum of patients with COPD when compared with non-
smokers: CXCL9 e 14.3 vs. 1.4 pg/mL, p< 0.001; CXCL10 e
16.9 vs. 3.7 pg/ml, p< 0.05; CXCL11 e 58.1 vs. 33.5 pg/ml,
p< 0.05; CCL5 e 59.9 vs. 33.5 pg/mL, p< 0.001. Further-
more, chemokine sputum concentrations in healthy
smokers, which were not significantly different from those
of COPD-affected subjects were significantly increased in
comparison with non-smoking controls (CXCL9 8.5 pg/ml;
CXCL10 11.3 pg/ml; CXCL11 49.8 pg/ml.; CCL5 63.0 pg/ml,Table 1 Chemokine levels in induced sputum of tobacco smo
smokers.
Healthy non-smokers Healthy smo
GRO-a 2 2 ng/ml 3.0 0.5 ng/
MCP-1 0.2 0.1 ng/ml 0.1 0.04 ng
IL-8 0.73 ng/ml 1.27 ng/ml
CXCL9 1.4 pg/ml 8.5 pg/mld
CXCL10 3.7 pg/ml 11.3 pg/mld
CXCL11 33.5 pg/ml 49.8 pg/mld
CCL5 33.5 pg/ml 63.0 pg/mld
a pZ 0.021 compared to healthy smokers.
b p< 0.05 compare to healthy smokers and non-smokers.
c p< 0.05 compared to healthy non-smokers.
d p< 0.05 compare to healthy non-smokers.p< 0.001).71 In addition, chemokine concentrations were
positively correlated with neutrophil numbers.
With regard to chemokine receptors, induced sputum
studies have shown that cells from normal non-smoking
subjects express chemokine receptor genes.71 In COPD, Leaky
et al. showed that sputum lymphocytes from COPD patients
and healthy non-smokers expressed activated phenotypes
[CD103 (adhesion molecule aEb7 integrin, the ligand for
epithelial cell E-cadherin) and CD69 (IL-2 receptor (IL-2R) b-
chain)]. However, lung lymphocytes in COPD expressed the
chemokine receptor CXCR3 at a lower level than healthy
controls.72 Contrary to the induced sputum study, Saetta and
Colleagues showed, in a small study of tissue biopsies, that T
cells infiltrating the peripheral airways of smokers with COPD
showed increased expression of the Th1 chemokine receptor
CXCR3,paralleledby theexpressionof its ligandCXCL10at the
epithelial level. CXCR3 expression was lower in healthy
smokers, and significantly lower in non-smoking controls.73
Thus, although, sputum chemokine measures are used as
a marker of airway inflammation and obstruction in smokers
and COPD patients, data on chemokine receptors in relation
to tobacco smoke exposure still need to be confirmed in
larger studies.Cytokines
Interleukin-1
IL-1 is one of the first cytokines ever described. The IL-1
superfamily is comprised of IL-1a, IL-1b, and the IL-1
receptor antagonist (IL-1RA), an anti-inflammatory mole-
cule competing for the receptor binding with IL-1a and IL-
1b. These factors are capable of increasing the expression
of adhesion molecules on endothelial cells and enabling
transmigration of leukocytes to sites of infection, hence
playing an important role in the inflammatory response. IL-
1 is involved in a variety of cellular activities, including cell
proliferation, differentiation, and apoptosis.
In the experimental setting, exposure to cigarette smoke
is capable of inducing lung macrophage activation and
chemotaxis in mice and the administration of anti-IL-1
antibodies is capable to down-regulate macrophage acti-
vation and the ensuing lung inflammation.74kers with COPD, healthy tobacco smokers and healthy non-
kers COPD smokers Reference
ml 31 11 ng/mlb 68
/ml 0.8 0.4 ng/mlb 68
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heightened systemic IL-1 production in blood mononuclear
cells75 and to stimulate local IL-1 responses by bronchial
epithelial cells as well. Interestingly, in an explanted
human bronchial epithelial cell assay, IL-1 release has been
found to be higher in smokers with COPD and non-smokers
compared to smokers with normal pulmonary function,
suggesting that smokers who develop COPD may be
particularly susceptible to tobacco smoke-induced inflam-
matory responses, including IL-1 release66; this observation
is in agreement with the results of an association study
between the IL-1 gene polymorphisms C-31T and IL-1
responses in smokers.76
Using mRNA amplification by a reverse transcriptase
polymerase chain reaction (RT-PCR) technique on lung
biopsies of COPD patients, higher IL-1b gene expression at
mRNA level was found in COPD compared to non-diseased
subjects, whereas no difference was found between
smoking and non-smoking controls.60
BAL studies have provided contrasting data. In the study
by Kuschner and Colleagues, supernatants and cells from
smokers exhibited increased levels of IL-1b in comparison
to non-smokers and this increase was dependent upon the
level of cigarette exposure.65 Similar data were obtained in
the study of Ekberg-Jansson and Colleagues, who showed
higher concentrations of IL-1 in conjunction with the
elevation of other inflammatory markers such as HNL
(Human Neutrophil Lipocalin), MPO and IL-8.77 In contrast,
the study of Mikunyia and Colleagues did not show any
change in the spontaneous ex-vivo release of IL-1 in
smokers and non-smokers, although it found a significant
decrease in the release of IL-1RA.78 Similarly, the study of
Brown and Coworkers showed that cigarette smoke could
decrease IL-1b release from alveolar macrophages.79 No
change in IL-1 levels in smokers compared to non-smokers
was found in the EBC study of Garey and Colleagues.80
Induced sputum studies. The expression of IL-1 in
bronchial cells recovered by induced sputum has been
assessed by Gelder and Colleagues who have shown that in
70% of normal subjects and in 100% of asthmatic subjects
IL-1 mRNA is expressed by inflammatory cells present in
induced sputum.69 No study investigating IL-1 expression in
induced sputum samples of healthy smokers has been
published so far.
Thus, although a number of studies, including BAL
suggest that tobacco smoke may induce IL-1 expression, no
induced sputum studies has actually shown IL-1 gene up
regulation in tobacco smoke exposed individuals.
Tumor necrosis factor-a
TNF-a is a pleiotropic cytokine of the TNF superfamily. The
main sources of TNF-a in vivo are monocytes, fibroblasts,
and endothelial cells. Macrophages, T-cells, B-lympho-
cytes, granulocytes, smooth muscle cells, eosinophils and
mast cells, also produce TNF-a after stimulation with
bacterial endotoxins, IL-1, platelet derived growth factor
(PDGF), oncostatin M and metals such as nickel and beryl-
lium. TNF-a plays a significant role in chronic bronchitis,
COPD, asthma, acute lung injury and its most severe form,
the acute respiratory distress syndrome.81
Several lines of evidence indicate that cigarette
smoke induces TNF-a gene expression. Heightened TNF-aexpression has been shown in human blood-derived immune
cells77 as well as in experimental animals,82 suggesting that
TNF-a may be central to smoke-induced inflammation and
to connective tissue damage in humans.
Induced sputum studies. Studies on induced sputum
have produced contrasting results. Gelder et al. (1995)
have shown that the TNF-a gene is normally expressed by
70% of sputum cells from normal non-smoking subjects.69
Dentener and Coworkers, evaluating the effect of smoke
upon TNF-a production have shown that cultured sputum
cells from COPD patients produced significantly less TNF-
a than healthy non-smoking subjects (0.3 ng/ml in the
steroid-free group and 1.0 ng/ml in the steroid-treated
group vs. 2.9 ng/ml; pZ 0.017 and pZ 0.001, respec-
tively), while no significant differences were found in TNF-
a production between sputum cells from COPD patients and
healthy smokers (2.0 ng/ml in the latter group, pZ 0.08).83
These results have been confirmed by Vernooy and
Coworkers, who found similar concentrations of TNF-a in
the induced sputum of COPD patients (total fraction 59 pg/
ml, bioactive TNF-a <15 pg/ml) and healthy smokers (total
fraction 57 pg/ml, bioactive TNF-a< 15 pg/ml).84 In
contrast, Keatings and Coworkers found increased concen-
trations of TNF-a in the induced sputum from COPD patients
compared with the smoking and non-smoking control
subjects.17 Similarly, in the study of Rovina and Colleagues
increased levels of TNF-a were found in the induced sputum
of COPD patients (50 pg/ml [17-75]) in comparison with
asymptomatic smokers (18.6 pg/ml [10-35], pZ 0.322) and
non-smokers (15.4 pg/ml [9e25], pZ 0.014).70
In summary, although an effect of smoke on the release
of TNF-a by immune cells has been shown, this effect has
not consistently been observed in induced sputum cells in
smokers without COPD (Table 2).
Granulocyte-macrophage colony-stimulating factor
Granulocyte-macrophage colony-stimulating factor (GM-
CSF) is a cytokine produced by macrophages, T cells, mast
cells, endothelial cells, and fibroblasts. GM-CSF induces the
production of type 1 pro-inflammatory cytokines in human
peripheral blood mononuclear cells, T lymphocytes, and
antigen presenting cells while down-regulating type 2
cytokines.85 GM-CSF prolongs neutrophil survival in a dose-
dependent fashion.86
Induced sputum studies. GM-CSF expression is activated
by exposure to tobacco smoke. A study of induced sputum
cells by Profita and Colleagues showed that sputum cells
isolated from patients with COPD released higher levels of
GM-CSF (599.5 [454e657] pg/ml) than sputum cells isolated
from healthy smokers (294 [253e325] pg/ml, pZ 0.0002),
which in turn released more GM-CSF than control subjects
(125 [100e150] pg/ml; p< 0.004 compared to healthy
smokers and p< 0.0001 compared to COPD, respectively).87
These data suggest that GM-CSF may play a role in main-
taining neutrophilic inflammation in the smoker’s lung
(Table 2).
Vascular endothelial growth factor
Vascular endothelial growth factor (VEGF) is a potent
morphogenic cytokine that modulates embryogenic angio-
genesis and vasculogenesis and is expressed in a variety of
cell types including epithelial cells and macrophages. VEGF
Table 2 Macrophage-derived cytokine levels in induced sputum of tobacco smokers with COPD, healthy tobacco smokers and
healthy non-smokers.
Healthy non-smokers Healthy smokers COPD smokers Reference
TNF-a n/a 57 pg/ml 59 pg/mla 84
TNF-a 2.9 ng/ml 2.0 ng/ml 0.3 ng/mlc 83
TNF-a 15.4 pg/ml 18.6 pg/ml 50 pg/mlb 70
GM-CSF 125 pg/ml 294 pg/mld 599.5 pg/mle 87
VEGF <250 pg/ml <400 pg/ml, pZ 0.56 <1000 pg/ml, pZ 0.046 70
VEGF 1350 840 pg/ml n/a 480 240f to 1360 800 pg/ml 92
n/a: not available.
a No statistically significant difference compared to healthy smokers.
b pZ 0.014 compared to healthy non-smokers.
c pZ 0.017 compared to normal controls, no significant difference compared to healthy smokers.
d p< 0.004 compare to normal non-smokers.
e pZ 0.0002, compared to healthy smokers.
f Very severe COPD (severe COPD 650 450 pg/mL; moderate COPD: 1,180 760 pg/mL; mild COPD: 1,360 800 pg/mL).
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constitutive VEGF expression is thought to be important in
maintaining normal homeostasis of the lung structure.
Elevated oxidative stress levels may induce a reduction of
lung VEGF levels, hence promoting the development of
emphysema,88 as tissue biopsy studies have shown that
decreased VEGF expression is associated with increased
apoptosis in the emphysematous lung.89
Consistent with the experimental data indicating that
cigarette smoke exposure disrupts the VEGF (165)eVEGFR-2
complex, VEGF tissue studies have shown a significant
reduction of VEGF levels in smokers and COPD patients
compared to non-smokers.90
Consistent with tissue studies, a BAL study by Nagai
et al. demonstrated that both alveolar macrophage VEGF
mRNA and VEGF protein in BAL fluid were significantly
decreased in current smokers compared to non-smokers.
VEGF expression in alveolar macrophages was also found to
be positively correlated with diffusing lung capacity for CO,
indicating a possible relationship between low VEGF
expression and parenchymal destruction.91
Induced sputum studies. In contrast with tissue and BAL
studies on lung VEGF, the induced sputum study by Rovina and
Coworkers showed that concentrations of VEGF were signifi-
cantly higher (w1000 pg/ml) in COPD than in asymptomatic
smokers (w400 pg/ml,pZ 0.024) andnon-smokers (w250 pg/
ml, pZ 0.002), while the difference between healthy smokers
and non-smokers was not significant (Table 2). The VEGF levels
in induced sputum in both groups of smokers (asymptomatic
and COPD smokers) were significantly correlated with smoking
history, as quantifiedbypack-years (rZ 0.56 vs. asymptomatic
smokers, pZ 0.046 vs. COPD). Interestingly, VEGF levels were
positively correlated with IL-8 (rZ 0.636, pZ 0.026, respec-
tively) and TNF-a levels (rZ 0.622, pZ 0.031, respectively).70
In contrast, Kanazawaet al. observed that induced sputum
VEGF levels decreased with the severity of COPD (mild COPD:
1360 800 pg/mL; moderate COPD: 1180 760 pg/mL;
severe COPD: 650 450 pg/mL; very severe COPD:
480 240 pg/mL) in comparison to healthy control subjects
(1,350 840 pg/mL;pZ 0.007 vs. severeCOPD,pZ 0.002vs.
very severe COPD).92
Further studies on patient populations characterized
for their smoking history may be necessary to ascertainthe role of VEGF as a marker of lung destruction and
emphysema.
Leptin
Leptin is the pleiotropic molecule sharing similarities with
cytokines such as IL-6, IL-11, which plays a regulatory role
in innate and acquired immunity, inflammation, and hae-
matopoiesis.93 Cigarette smoking is known to depress leptin
levels in smokers,94 suggesting that cigarette smoking may
increase sensitivity to leptin, as cigarette smokers have
been found in a study to have lower leptin levels than non-
smokers with the same BMI.95,96 Consistent with the
knowledge that leptin production is acutely increased
during infection and inflammation, COPD patients have
been found to have higher plasmatic levels of leptin during
exacerbations.97
Induced sputum studies. Broakhuizem and Coworkers
found that leptin could be detected in induced sputum of
10 out of 14 patients with moderate COPD. Statistically
significant relationships were found between sputum leptin
and CRP (rZ 0.943, p< 0.001) and total TNF-a (rZ 0.690,
p< 0.01).98 However, no study has been carried to deter-
mine the effect of smoking upon LRT tract leptin levels,
using smoking and non-smoking healthy controls.
Other growth factors
Transforming growth factor-beta 1 (TGF-b1)
TGF-b1 is a potent anti-inflammatory cytokine produced by
several cell lineages, including AM. TGF-b1 also has
powerful profibrotic activities since it causes smooth
muscle cell hyperplasia, collagen production by fibroblasts,
and differentiation of fibroblasts to myofibroblasts, cells
that are important in both matrix production and extra-
cellular matrix (ECM) contraction.99 Tobacco smoke affects
the cytokine secretion as shown in a rat tracheal explant
model, where cigarette smoke caused release of active
TGF-b1, that was preventable by the oxidant scavenger
tetramethythiourea within 1 h after exposure.100
In vitro studies of peripheral blood mononuclear cells
exposed to cigarette smoke for 1e5 min have shown that the
secretion of TGF-b1 was higher in smokers than in non-
smokers.101 However, in a BAL study of Pons and Coworkers
where flow cytometry-sorted alveolar macrophages were
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COPD released significantly less TGF-b1 than smokers with
normal lung function and non-smokers.102 No TGF-b1 studies
on induced sputum in healthy smokers are yet available.
Hepatocyte growth factor (HGF)
HGF, a heterodimeric protein obtained through the cleavage
of an inactive precursor, called 90-kD proHGF by serine
protease cleavage, that has been shown to control prolifer-
ation and migration of type II pneumocytes and their differ-
entiation into type I pneumocytes. In a rat model, decreased
HGF expression is associated with emphysema.103
In contrast with experimental studies suggesting that
HGF might represent a marker of susceptibility to emphy-
sema in smokers, a lung tissue study by Bonay and
Colleagues showed no differences in HGF expression at the
mRNA or the protein level between emphysema patients
and non-emphysema controls, irrespective of smoking
history.104 No studies on HGF in induced sputum in smokers
have been reported so far.
Lymphocyte-derived cytokines
IL-4, an 18 kDa glycoprotein, and IL-13, a 13 kDa glycoprotein
produced by Th2-lymphocyte and by some epithelial cells,
have similar effects, among which a potent inhibitory effect
on macrophages. IL-13 over expression in transgenic mice is
capable of inducing the development of spontaneous emphy-
sema, with mucous metaplasia and inflammation driven by
the influx of macrophages and CD8 T-cells in the lung.105,106
Tobacco smoke has been shown to have systemic effects
upon IL-13 production, as increased levels of IL-13 could be
found in serum of smokers in a monozygotic twin study.107
Furthermore, Miotto and Coworkers showed in a lung biopsy
study of smokers with COPD and asymptomatic smokers
that the IL-13 and the IL-4 genes were expressed at slightly
higher levels in COPD compared to healthy smokers. In
contrast, the IL-5 and the IFN-g genes were expressed at
similar levels in COPD and healthy smokers.108 Similar
results have been obtained by Barcelo and Coworkers in
a BAL study, showing that COPD patients had higher
percentages of IL-13-positive T lymphocytes compared to
never smokers or smokers with normal lung function,
whereby the expression of IL-13 was inversely related to
the degree of airflow obstruction.109 In stark contrast, the
study of Boutten and Colleagues on IL-13 and IFN-g
expression in tissue homogenates of emphysematous lungs
showed that while IFN-g expression was similar in emphy-
sematous smokers, healthy smokers and non-smoking
controls, the expression of IL-13 mRNA expression was
significantly lower in emphysematous smokers compared to
healthy smokers and non-smoking controls. Interestingly,
no differences were found between smoking and not
smoking controls.110
Consistent with the lymphocyte cytokine data, STAT4,
a member of STAT family of transcription factors involved
in the immune system regulation, has been implicated in
COPD by Di Stefano et al., who found a significant increase
in the number of phospho-(Y-693)STAT4-positive cells in the
sub mucosa of COPD patients in comparison to healthy
smokers and non-smokers, in a BAL and bronchial biopsy
study. Similar results were obtained from bronchial
epithelium and BAL cells: COPD subjects showed asignificantly higher level of STAT4 expression and activation
than non-smokers and healthy smoker. Interestingly, the
number of phospho-(Y-693) STAT4 immunoreactive cells in
the sub mucosa of smokers was inversely correlated with
FEV1 (% pred) values.
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Further studies are needed to clarify the potential role
of IL-13 as a marker of tobacco smoke-induced lung
damage. No induced sputum studies have been reported yet
assessing IL-13, nor IL-2, IL-4, and IFN-g expression in the
LRT of smokers with or without COPD.Oxidants and oxidative stress related factors
Myeloperoxidase
MPO is the most abundant component in the azurophilic
granules of leukocytes and it is found not only in neutro-
phils but also in monocytes and in some subtypes of tissue
macrophages. MPO is secreted upon leukocyte activation,
amplifies the oxidative potential of H2O2 derived from
leukocyte NADPH oxidases, xanthine oxidase, uncoupled
nitric oxide synthase (NOS) and various Nox isoenzymes, by
forming potent oxidants capable of chlorinating and
nitrating phenolic compounds. MPO-derived diffusible
radical species are capable of initiating lipid peroxidation
as well as promoting an array of post-translational modifi-
cations in target proteins, including halogenation, nitration
and oxidative cross-linking.112
Induced sputum studies. Two studies have been pub-
lished on MPO analysis in induced sputum. Rytila and
Colleagues reported that the numbers of MPO positive cells
was greater in the induced sputum from asymptomatic
smokers compared to non-smokers (pZ 0.003), while no
statistically significant differences were observed between
smokers and ex-smokers and between healthy smokers and
stage 0 COPD subjects.113
In another study from Hill et al., performed on subjects
with chronic bronchitics with and without a-1 antitrypsin
deficiency, MPO concentrations in induced sputum were
higher in currently smoking bronchitics (0.3 units/ml)
compared to who stopped smoking (0.1 units/ml), although
the difference did not reach statistical significance.114
The lack of statistically significant differences between
current and former smokers with COPD was confirmed by
another study, which observed similar concentrations of
MPO in the induced sputum of the two groups.115
Further studies could help clarifying the relationship
between exposure to tobacco smoke, COPD stages and MPO
expression. Furthermore, since the study of Van Schooten
and Coworkers has shown that the MPO-463G/A genetic
polymorphism is associated with MPO activity in the LRT as
well as with the levels of smoking-related DNA adduct
found in lung-derived cells, it would be reasonable to take
into account the distribution of the MPO-463G/A genetic
polymorphisms in assessing MPO expression in relation to
tobacco smoke exposure.116
Eosinophil peroxidase (EPO)
EPO is a member of a family of mammalian peroxidases
that includes MPO, lactoperoxidase (LPO), and thyroid
peroxidase (TPO) and has been implicated in promoting
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conditions, including asthma.
Induced sputum studies. EPO has been implicated in
lung inflammation mediated by eosinophils, and although
its expression is typically higher in asthmatic patients,
higher levels of the enzyme were also detected by Keatings
and Colleagues in the induced sputum from COPD subjects
in comparison with healthy controls.117 In this context it is
worth noticing that the bronchial biopsy study by Amin and
Coworkers has shown that EPO was increased in asymp-
tomatic smokers compared to non-smoking subjects, thus
suggesting a role of eosinophils and their products,
including EPO, in the remodelling of the smoker’s
airways.118 Currently EPO is used as a marker of eosinophils
in the induced sputum and other biological samples.119
Further studies are needed in order to assess the role of
EPO as a marker of tobacco smoke-induced inflammation.
Superoxide dismutase (SOD)
The enzyme SOD catalyzes the dismutation of superoxide
into oxygen and hydrogen peroxide. SOD is an important
component of the antioxidant defense system in cells
exposed to reactive oxygen species (ROS). In humans, three
forms of SOD are present: SOD1 is located in the cytoplasm,
SOD2 in the mitochondria and SOD3 in extracellular
spaces.120 Extracellular SOD is expressed at particularly
high concentrations in the lungs, where it has been
demonstrated in bronchial lining fluid, in epithelium of
airways, and in pulmonary blood vessel walls by immuno-
histochemistry. This pattern of expression may reflect the
importance of extracellular SOD in lung defenses against
endogenous oxidative stress as well as against exogenous
oxidative stress caused by inhaled air pollutants such as
tobacco smoke.121
BAL and blood studies have shown that SOD1 and SOD3
expression is reduced in the lung and the blood of tobacco
smokers. In a study performed by Di Silvestro and
Coworkers on BAL samples from normal non-smokers,
healthy smokers and asthmatic subjects, SOD activity was
detected in all samples. Unlike serum or some other fluids,
in which the enzyme SOD3 accounts for virtually all SOD
activity, SOD1 accounted for virtually all SOD activity in the
BAL fluid. Interestingly, SOD activity was lower in smokers
than in non-smoking controls or asthmatics, suggesting an
important role of cigarette smoke in reducing the local
anti-oxidative power in the lung.122
The above lung data were confirmed in the study of Kim
and Colleagues, in which extracellular SOD activity was
quantified on blood samples and SOD3 was found to be
lower in smokers in comparison with age-matched non-
smokers, suggesting a negative effect on the oxidant
defense systems.123
In contrast, the study of Hulea and Coworkers on blood
samples from 200 subjects, smokers and non-smokers,
showed that while in smokers of 18e45 years of age the
changes of the plasma pro-oxidant and antioxidant
parameters were not significantly different from those of
the age-matched controls, in the 46e80 age group they
were. In smokers, both antioxidant erythrocyte enzymes,
glutathione peroxidase (GSH-Px) and SOD, exhibited
increased activity in the 18e45 age group and decreased
activity in the 46e80 age group.124No study has been yet published on SOD expression in
induced sputum in smokers versus non-smokers.
Glutathione S-transferase
The glutathione S-transferase (GST) family of enzymes
comprises a long list of cytosolic, mitochondrial, and
microsomal proteins catalyzing the conjugation of
reduced glutathione via the sulfhydryl group to electro-
philic centers on a wide variety of substrates, both
endogenous and xenobiotic. An activity that’s useful in the
detoxification of endogenous compounds such as peroxi-
dized lipids as well as in the metabolism of xenobiotics, in
particular in protecting against oxidative damage from
tobacco smoke components. A number of polymorphisms
of the GST genes have been identified which are associ-
ated with the levels of enzymatic activity and with lung
cancer and emphysema/COPD risk.125,126 Although GST
might represent an interesting marker of the response of
the LRT to tobacco smoke exposure, no induced sputum
studies have been published so far.
Cytochrome P450 1A1 and P450 1A6
Cytochrome P450 enzymes catalyze the first step of the
metabolism and subsequent elimination of hydrophobic
xenobiotics. However, the activity of some isoforms,
including Cytochrome P450 1A1 (CYP1A1), may result in
cellular insults such as oxidative stress and activation of
procarcinogen compounds into reactive metabolites.
CYP1A1 is involved in the biotransformation of tobacco-
derived polycyclic aromatic hydrocarbons (PAH) into
carcinogenic metabolites. CYP1A1 is inducible by PAHs
(Polycyclic aromatic hydrocarbons) and it is presumed to be
important in pulmonary carcinogenesis. The CYP1A1-
dependent monooxygenase transforms selected xenobiotics
(including PAHs procarcinogens) into potent carcinogenic
metabolites. CYP1A1 is induced in the lung up to 100-fold
by tobacco smoking.127e129 No studies have been reported
so far on the analysis of lung CYP1A1 gene expression
using sputum induction or other non-invasive sampling
procedures.
Isoprostanes
8-Isoprostane is the best characterized compound
belonging to F2-isoprostanes, a group of stable Prosta-
glandin F2a (PGF2a) isomers formed by the free radical
peroxidation of arachidonic acid independent of the action
of cycloxygenase. 8-Isoprostane is considered an ideal
marker for investigating the pathophysiology of oxidative
injury. Although 8-Isoprostane may be produced by cyclo-
xygenase (COX)-1 and COX-2 activity in some cells and
tissues, it can be considered a reliable biomarker of lipid
peroxidation caused by ROS.130
Induced sputum studies. Levels of 8-isoprostane have
beenmeasured in induced sputum. In a recent study, Kinnula
and Coworkers found that 8-isoprostane levels in induced
sputumwerehigher in healthy smokers (108.4 pg/mL) than in
non-smokers (15.3 pg/mL, pZ 0.005), who were not signifi-
cantly different from ex-smokers. Interestingly, healthy
smoker levels were not significantly different from stage
0 COPD subjects (66.6 pg/mL). In contrast, 8-isoprostane
levels were significantly increased in COPD (202.2 pg/mL in
stage IeIII, p< 0.0001 and pZ 0.02 compared with non-
1602 A. Comandini et al.smokers and healthy smokers, respectively). In addition,
a statistically significant correlation was found between
8-isoprostane levels, lung function parameters (FEV1/FVC
rZ0.66, p< 0.0001; FEV1 rZ0.48, pZ 0.006) and
smoking history (pack-years, rZ 0.56, pZ 0.001). Finally,
8-isoprostane sputum levels were positively correlated with
neutrophils counts in sputum (total neutrophils rZ 0.37,
pZ 0.02)131 (Table 3).
Similar data were obtained by Montuschi and
Colleagues, in an EBC cross-sectional study evaluating the
non-smoking and smoking controls in comparison with
current smokers with COPD. In this study, 8-Isoprostane
levels were detectable in the EBC of healthy non-smokers
and were increased in healthy smokers, COPD ex-smokers
and COPD current smokers. In ex-smokers with COPD and
current smokers with COPD, 8-Isoprostane was higher than
in healthy smokers. 8-Isoprostane levels in COPD ex-
smokers and current smokers were similar. Interestingly,
EBC 8-isoprostane concentrations increased 15 min after
smoking, compared to basal levels.21 In conclusion, 8-iso-
prostane measures in EBC appear to be a non-invasive and
reliable measure of oxidative stress and a candidate marker
of tobacco smoke-induced lipid peroxidation.
Reactive nitrogen species (RNS)
Increased production of NO during inflammatory and
immune processes affecting the respiratory tract can cause
respiratory tract injury thus contributing to the patho-
physiology of inflammatory airway diseases, as NO can
react with superoxide anion released from inflammatory
cells, yielding the potent oxidant peroxynitrite. Peroxyni-
trite adds a nitro group to the 3-position adjacent to the
hydroxyl group of tyrosine to produce the stable product
nitrotyrosine. NO also reacts directly with O2 to form
nitrite, the oxidation of which, by neutrophil-derived MPO
or by other related peroxidases, yields nitryl chloride and
nitrogen dioxide. Although nitration of tyrosine is generally
attributed to peroxynitrite, the peroxidase-dependent
nitrite oxidation pathway is also involved.
Induced sputum studies. Nitrotyrosine is considered an
indicator of the production of RNS: in COPD patients, the
numbers of nitrotyrosine-immunopositive cell have been
shown to be related to the number of iNOS-positive cells
and to airflow reduction (FEV1).
132 Nitrotyrosine-tagged
cells have been measured in induced sputum studies
showing markedly positive reactions for iNOS and nitro-
tyrosine in smokers as compared to non-smokers. In




Nitrotyrosine-tagged cells <0.01 106/g
n/a: not available.
a pZ 0.005, compared to non-smokers.
b p< 0.0001 compared to non-smokers and pZ 0.02 compared to h
c Stage 0 COPD (66.6 pg/mL).
d pZ 0.004 compared to non-smokers.than in non-smokers (pZ 0.004, respectively). In addition,
there was a statistically significant difference between
never smokers and ex-smokers (pZ 0.04), while there was
no significant difference between asymptomatic smokers
and stage 0 COPD subjects. Similarly, smokers showed a
higher number of nytrotyrosine-positive cells than non-
smokers (pZ 0.003), while there was no difference
between healthy smokers and stage 0 COPD subjects or
between never smokers and ex-smokers. The total number
of iNOS-positive cells was negatively correlated with airflow
measures [MEF-50 (rZ0.567, pZ 0.006)].113
The available data suggest that oxidative stress imposed
by RNS may be exaggerated in the airways of current
smokers and in COPD patients. Further, because the counts
of nitrotyrosine-positive cells were significantly correlated
with the airway obstructive changes in COPD, hyper
production of RNS may be an important factor in the
pathogenesis of COPD. NO produced in the airways,
presumably via iNOS, is consumed by its reaction with
superoxide anion and/or peroxidase-dependent mecha-
nisms. However, no major differences could be observed




Alpha-1-antitrypsin (a-1-AT) is a serine protease and trypsin
inhibitor protecting the lung parenchyma from the action
proteases, chiefly of neutrophil elastase. a-1-AT concen-
tration in the blood varies from 150 to 350 mg/dL. Emphy-
sema is associated with inherited a-1-AT deficiency and
inactivation of a-1-AT has been postulated as a risk factor
for developing emphysema among smokers with normal
levels of a-1-AT.133
Induced sputum studies. In the study of Vignola and
Coworkers, a-1-AT levels were found to be elevated in
chronic inflammatory disorders of the lung such as COPD and
asthma as compared to normal controls, although no
difference was found between the a-1-AT levels of asymp-
tomatic smokers and those of non-smoking controls.134 The
results of this study are at odds with those obtained in BAL
and serum studies where a-1-AT levels were found to be
increased in active smokers. In this regard, Olsen et al.
have shown that the concentration of a-1-AT was increased
in the BAL fluid of smokers compared to non-smokers
(0.306 0.057 vs. 0.184 0.025 mg/100 cc, pZ 0.06),tobacco smokers with COPD, healthy tobacco smokers and
Healthy smokers COPD Reference
108.4 pg/mLa 202.2 pg/mlb,c 131
<0.05 106/gd n/a 113
ealthy smokers.
Tobacco smoke biomarkers in induced sputum 1603suggesting that increased a-1-AT levels in the LRT of ciga-
rette smoker might be protective against proteolysis.24 The
fundamental study of Ogushi and Colleagues on BAL fluid and
plasma showed that while smoker plasma a-1-AT had similar
activity as that of non-smokers, a-1-AT from the LRT of
smokers had significantly lower activity than that of non-
smokers. The a-1-AT from the BAL of smokers was signifi-
cantly less active than that of autologous plasma, suggesting
that cigarette smoking may be associated with a decrease in
the LRT neutrophil elastase (NE) inhibitory capacity, thus
increasing the vulnerability of the lung to elastolytic
destruction and the risk of developing emphysema.133
Thus, the data regarding the levels of a-1-AT in the
alveolar spaces, in the serum and the bronchial mucosal
surface raise questions on the effect of tobacco smoke
exposure upon this key protective enzyme, although the
discrepancy between induced sputum and BAL data may be
related to the different compartments of the respiratory
tract sampled by different procedures.
Alpha-1-antichymotrypsin
Alpha-1-antichymotripsin (a-1-AC) is a serine protease
inhibitor of chymotrypsin-like proteinases, including
pancreatic chymotrypsin, neutrophil cathepsin G, mast cell
chymasethat is synthesized by hepatocytes and alveolar
macrophages.
In a genetic study among the Swedish population, a-1-AC
deficiency was found be transmitted with an autosomal
dominant inheritance pattern. Interestingly, gene muta-
tions have been associated with increased prevalence of
COPD.135e138
No induced sputum studies have been yet published on
a-1-AC levels in tobacco smokers.
Secretory leukocyte proteinase inhibitor
Secretory leucoprotease inhibitor (SLPI) is a serine pro-
tease inhibitor produced in the lung by tracheal, bronchial,
bronchiolar epithelial cells, type II pneumocytes cells
as well as by monocytes, alveolar macrophages and
neutrophils. In addition to its antiprotease action, SLPI has
antibacterial properties against Gram-positive and Gram-
negative bacteria and is up-regulated by ‘‘alarm signals’’
such as bacterial lipopolysaccharides and cytokines.
Susceptibility of SLPI to cigarette smoke was demon-
strated by Cavarra and Colleagues who have shown in
a mouse model that cigarette smoke exposure reduces by
50% SLPI inhibitory activity.139 In a BAL study on normal
non-smoking volunteers, Vogelmeier and Coworkers showed
that SLPI is present in the lung epithelial fluid, at levels
similar to those of a1-AT, although more than 50% of the
antiprotease recovered by BAL is inactive.140
Induced sputum studies. Culpitt and Coworkers evalu-
ated the concentration of SLPI in the induced sputum of
a group of COPD patients. These authors showed that this
enzyme could be measured in induced sputum.141
No data are yet available on induced sputum SLPI levels
in healthy smokers or non-smoking controls.
Alpha-2-macroglobulin
Alpha-2-Macroglobulin (a-2-M) is a large plasma protein
produced by the liver that is comprised of four identical
subunits bound together by SeS bonds, capable ofinactivating a variety of proteinases, including serine-,
cysteine-, aspartic and metalloproteinases. The a-2-M
structure includes a 35 amino acid ‘‘bait’’ region which
is cleaved by proteinases making them susceptible of
being captured by a-2-M so that the proteinase-a-2-M
complex is recognized by macrophage receptors and
cleared.142,143
Modulation of a-2-M expression in response to tobacco
smoke exposure was suggested by Tappia and Coworkers
who showed that plasma concentrations of a-2-M are
increased in smokers, compared to non-smokers.144
Induced sputum studies. Measurable levels of a-2-M
have been detected in I.S. samples of healthy non-smoking
subjects (2.72 1.01 mg/ml) by Halldorsdottir and
Coworkers,145 and the quantification of the levels of a-2-M
in I.S. has been proposed as a marker of bronchial exuda-
tion in asthma research.146
No data on the levels of a-2-M in induced sputum in
smokers are yet available.
Matrix metalloproteinases and tissue inhibitor of
metalloproteinases
Metalloproteinases (MMPs) are a family of structurally
related enzymes capable of degrading all components of
the ECM; more than twenty members of the MMP family
have been identified so far. The enzymes of the MMP family
share 32e49% amino acid similarity and have similar
structural domains. MMP-9, that is predominantly produced
by macrophages and is also found in neutrophil granules, is
the major elastolytic MMP. Lung macrophages and epithe-
lial cells produce tissue inhibitors of metalloproteinases
(TIMPs) which selectively inhibit MMPs. MMPs and TIMPs,
which are thought to play key roles in tissue remodelling of
the airways in COPD and asthma patients, been shown to be
induced by oxidants, including peroxynitrite and hydrogen
peroxide, bacterial products such as LPS, by cytokines
including IL-1b, PDGF and TNF-a.147
Induced sputum studies. With regard to the MMPs
capable of degrading elastase i.e, MMP-2, MMP-7, MMP-9
and MMP-12, a number of studies have looked at their
expression and concentrations in cells and supernatants
obtained by sputum induction (Table 4).
Aviles and Colleagues evaluated normal non-smoking
controls, healthy smokers and COPD patients for MMP
expression in induced sputum. Healthy smokers were found
to have a higher concentration of total MMP-9
(273 277 ng/ml vs. 128 146 ng/ml) than non-smoking
controls. Patients with COPD had the highest concentra-
tions of total (477 262 ng/ml) and active MMP-9
(178 126 ng/mL), compared to both healthy smokers and
non-smoking controls (p< 0.05). In the same study, healthy
smokers were found to have a higher ratio of total MMP-9 to
TIMP-1 (0.16 0.14 vs. 0.08 0.06) than non-smoking
controls; patients with COPD had the lowest concentrations
of TIMP-1 (1.044 1.036 mg/ml). When all groups were
considered together, there was an inverse relationship
between the MMP-9/TIMP-1 ratio and airflow measures
(FEV1); when the COPD group in isolation was considered,
the correlation was stronger (rZ0.56; pZ 0.002), and an
even stronger correlation was observed when the extent
of smoking history was taken into account (rZ0.81;
p< 0.0001).148
Table 4 Proteinases in induced sputum of tobacco smokers with COPD, healthy tobacco smokers and healthy non-smokers.
Healthy non-smokers Healthy smokers COPD non-smokers COPD Reference
MMP-9 n/a 41%a n/a 76%a,e 150
MMP-9 128 146 ng/ml 273 277 ng/ml n/a 477 262 ng/mle 148
MMP-12 4.2 ng/ml 6.7 ng/ml n/a 17.5 ng/ml 152
MMP-8 n/a 6%a n/a 35%a,e 150
NE activity n/a n/a 36.4 12.0 nmol/lb 346.2 72.1 nmol/le 115
NE/inhibitor complex 0.21 0.03b mg/mgc 0.23 0.07 mg/mg n/a 0.52 0.10d,e mg/mg 160
n/a: not available.
a % of subjects with MMP activity.
b Former smokers.
c Per mg albumin of BAL fluid.
d Smokers with subclinical emphysema.
e p< 0.05 in comparison with other groups.
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MMP-9 levels were significantly elevated both in asymp-
tomatic smokers compared to non-smokers (pZ 0.01) and
in Stage 0 COPD as well (p< 0.001); there was no difference
however between healthy smokers and smokers with
COPD.149 A study by Vernooy and Coworkers confirmed the
expression of MMP-9 activity in the induced sputum of
healthy smokers and mild-to-moderate COPD patients: they
found that mean total MMP-9 activity was significantly
higher in the COPD group when compared to that of the
healthy smokers group (p< 0.05) and that active MMP-9 was
detectable in 76% of COPD patients compared to 41% of
healthy smokers (p< 0.05), whereas MMP-2 activity was
below the detection threshold.150
The elevation of the expression of MMP-9 in COPD was
confirmed in a study by Vignola and Coworkers, where the
analysis of the levels of MMP-9 and TIMP-1 in the induced
sputum of patients with chronic bronchitis and healthy non-
smokers showed that MMP-9 and TIMP-1 levels were signif-
icantly increased in COPD (80.5 vs. 23 ng/ml, p< 0.008, and
475 vs. 60 ng/ml, p< 0.0003).151 However this study did not
evaluate healthy smokers.
Demedts and Colleagues evaluated MMP-12 in induced
sputum from non-smoking controls, healthy smokers and
COPD patients. Non-smokers (4.2 ng/ml), healthy smokers
(6.7 ng/ml) and former smokers (6.1 ng/ml) had signifi-
cantly lower levels of MMP-12 than patients with COPD
(17.5 ng/ml), although there were no significant differ-
ences in MMP-12 levels among the three control groups.
Interestingly, MMP-12 levels in induced sputum from COPD
patients who were actively smoking (16.1 ng/ml) did not
differ significantly from those in COPD patients who had
quit smoking (18.2 ng/ml, pZ 0.87). Furthermore, MMP-12
specific activity (detected by cleavage of a fluorescence
quenched substrate) was significantly higher in COPD
patients than in controls (4.11 vs. 0.14 mg/ml, pZ 0.0002).
As in other studies, an inverse correlation was found
between MMP-12 protein levels in induced sputum and
airflow measures.152
MMP-12-expressing cells in induced sputum were quan-
tified by immunocytochemical staining by Babusyte and
Colleagues, who showed that healthy smokers had higher
percentages of MMP-12 positive cells than healthy never
smokers. Further, COPD smokers had a higher number of
MMP-12-expressing cells than COPD ex-smokers, althoughthe difference was not statistically significant. The
numbers of MMP-12 positive macrophages correlated with
the numbers of pack-years in COPD smokers (rZ 0.54,
p< 0.05), COPD ex-smokers (rZ 0.64, p< 0.05) and
healthy smokers (rZ 0.78, p< 0.05).153
Culpitt and Colleagues were able to confirm that the
levels of MMP-9 and TIMP-1 were significantly higher in
normal smokers compared to non-smoking controls. They
also found that the levels of MMP-1, MMP-8, in addition to
MMP-9 and TIMP-1, were significantly higher in the induced
sputum of COPD patients than in healthy smokers or non-
smoking controls.154
TIMP-1 was also measured in the studies of Boschetto
and Coworkers, who showed no significant differences in
the concentration of TIMP-1 in induced sputum of COPD
patients with and without emphysema (2.3 vs. 7.5 ng/ml) in
comparison to non-smoking controls,155 and of Vignola and
Colleagues who detected TIMP-1 in induced sputum COPD
patients.156 Neither study assessed TIMP-1 expression in
healthy smokers.
With regard to the MMPs capable of degrading triple
helix native collagen i.e. MMP-1, MMP-8 and MMP-13, the
study by Vernooy and Coworkers showed that active MMP-
1 could be found in a small proportion of COPD patients
and healthy smokers while MMP-8 was the dominant MMP
collagenase in both COPD patients and healthy smokers.
The mean total MMP-8 activity was significantly higher in
the COPD group (p< 0.05), and active MMP-8 was found
in 35% of the COPD patients compared to 6% of the
healthy smoker controls (p< 0.05), whereas MMP-2 and
MMP-13 activities were below the detection threshold.
When subjects were classified according to their current
smoking behavior, and MMP activity was compared, no
differences in the activity were observed between indi-
viduals who were current smokers and those who were
ex-smokers in both groups (COPD patients and healthy
subjects). A significant correlation between both active
and total MMP-8 and MMP-9 activity with the absolute
number of neutrophils was observed in the sputum of
COPD patients (rZ 0.668, pZ 0.003 and rZ 0.655,
pZ 0.004, respectively).150
In the Ilumet’s study, only MMP-8 induced sputum
concentrations differentiated GOLD Stage 0 COPD patients
from asymptomatic smokers (pZ 0.02). Interestingly, MMP-
8 levels correlated significantly with alterations in small
Tobacco smoke biomarkers in induced sputum 1605airway flow parameters (MEF-50, MEF-25) (pZ 0.005 and
pZ 0.0004), which are considered a good measure of
bronchial obstruction in COPD, and with markers of
neutrophil activation such as MPO and lactoferrin.149
Thus, MMP-9, MMP-12 and MMP-8 appear to be expressed
at higher levels in COPD patients compared to healthy
smokers. While MMP-9 is over-expressed in healthy smokers,
MMP-8 may differentiate GOLD Stage 0 COPD, i.e., subclin-
ical chronic obstructive bronchitis from healthy smokers.
Induced sputum data were confirmed by a BAL study by
Russell and Coworkers who examined the production and
activity of MMP-9 from in vitro stimulated macrophages in
smokers with COPD, healthy smokers, and non-smokers,
found that alveolar macrophages from COPD patients had
a significantly greater level of MMP-9 activity than healthy
smokers and non-smokers, with macrophages from healthy
smokers releasing higher levels of MMP-9 than macrophages
from non-smokers.157 Similar data were also obtained for
MMP-12 by Babusyte and Colleagues who confirmed the
results in the two different tissue compartment: sputum
induced and BAL.153
Neutrophil elastase (NE)
Human NE is a 29 kDa serine protease stored in azurophilic
granules of mature neutrophils that’s capable of intracel-
lular degradation of proteins during phagocytosis and
extracellular degradation of connective tissue during an
inflammatory process. Being able of destroying cross-linked
elastin and the major forms of collagen, NE is required
both for normal tissue turnover and for host defense, but it
is also potentially harmful for its ability to destroy
normal tissues. As such, it plays a central role in the
pathogenesis of pulmonary emphysema by destroying the
alveolar once anti-proteases such as a-1-AT are inactivated.
Tobacco smoke has both acute and chronic effects on NE
expression. Weitz and Colleagues evaluated the levels of
the NE-derived fibrinogen peptide A-a-1-21 in healthy
volunteers to find fivefold higher levels in smokers
compared to non-smokers (2.0 nmol/L vs. 0.4 nmol/L;
p< 0.0001). Smoking three cigarettes after 12 h of absti-
nence induced a marked raise in fibrinopeptide levels
(1.8 nmol/L vs. 0.4 nmol/L; p< 0.0001).158 Similarly, Hind
and Coworkers evaluated NE concentrations in current
smokers, ex-smokers and never smokers and showed that
smokers had significantly higher NE concentrations in
plasma than ex-smokers or never smokers. Interestingly,
higher NE levels were associated with lower FEV1 and
a higher annual decline in FEV1 in the preceding 10 years.
159
Induced sputum studies. The NE activity in induced
sputum was measured by Van Overveld and Coworkers in
a population including current and former smokers with
COPD. Although asymptomatic smokers and non-smokers
were not evaluated in this study, this report indicated that
NE was markedly elevated in current smokers versus former
smokers with COPD (36.4 12.0 vs. 346.2 72.1 nmol/l)115
(Table 4).
In addition, Vignola and Coworkers found that in healthy
smokers the level of total and active elastase were signifi-
cantly higher than in controls subjects (p< 0.03, p< 0.002,
respectively), but significantly lower than in chronic bron-
chitis patients (p< 0.006, p< 0.002, respectively).134 The
data seem to confirm those reported in a study performedon BAL fluids by Yoshioka et al., who found that NE-a1-
protease inhibitor complex concentrations were signifi-
cantly increased in smokers with subclinical emphysema
(0.52 0.10 mg/mg albumin) compared to ex-smokers
(0.21 0.03 mg/mg albumin, p< 0.01).160Leukocyte pro-inflammatory and antibacterial
products
Leukotriene B4
LTB4, a dihydroxy fatty acid derived from arachidonic acid
through the 5-LO pathway, is released by neutrophils and
macrophages and plays a regulatory role in the immune
response to antigenic stimulation; it is a potent chemotactic
and chemokinetic agent for human polymorphonuclear
leukocytes and a margination factor for monocytes and
macrophages. In addition, LTB4 stimulates cytotoxic T cell,
natural killer cell and suppressor T cell activity.
With regard to the source of airway LTB4, Laviolette and
Coworkers evaluated lung alveolar macrophages obtained
from smokers and showed that they released 80 to 90% less
LTB4 in vitro, as compared to non-smoker macrophages. In
contrast, blood polymorphonuclear leukocytes from
smokers and non-smokers showed no difference in the
synthesis of 5-lipoxygenase products,161 a finding confirmed
by Tardif et al.162
Induced sputum studies. The levels of LTB4 in the airways
were evaluated, by Kostikas and Colleagues, in a population
of COPD patients and healthy smokers. This study showed
that COPD patients had significantly higher levels of LTB4
(2.64 0.6 pg/mL) in comparison with healthy smokers
(1.45 0.4 pg/mL, p< 0.0001).163 LTB4 values were higher
in COPD patients with reversible airway obstruction
(3.07 0.3 pg/mL) compared to patients without airflow
reversibility (2.24 0.5 pg/mL,pZ 0.002). Values of LTB4 in
the sputum supernatant of patients with reversible and non-
reversible COPD presented a significant positive correlation
with sputum neutrophil levels (rZ 0.71, pZ 0.001). The
study might suggest that 5-lipoxygenase products are
released at higher levels in smokers. However, non-smoking
controls were not evaluated in the study.
In this regard, the EBM study of Carpagnano and
Colleagues, evaluating the levels of LTB4 in healthy
smokers and non-smokers, showed increased LTB4 levels
(9.4 0.4 pg/mL) in smokers compared to non-smokers
(6.1 0.3 pg/mL, p< 0.001).164 Further studies may
confirm the role of tobacco smoke in augmenting leuko-
triene levels in the airways of smokers and COPD patients.
Human neutrophil lipocalin
HNL, also called neutrophil gelatinase-associated lipocalin
(NGAL), is a specific constituent of neutrophilic granulocyte
granules.165 HNL is secreted more readily from the
neutrophils than any other neutrophil specific marker and
increased concentrations of HNL have been seen in sera of
patients with acute bacterial infections.166,167 HNL can be
used as a neutrophil marker in biological samples.119
Induced sputum studies. A study from Keatings and
Colleagues showed that HNL was markedly elevated in the
induced sputum from patients with COPD compared to non-
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tomatic smoker control group.
In this regard, a BAL study from Ekberg-Jansson and
Coworkers showed that concentrations of HNL were higher
in healthy smokers (with normal FEV1) than in non-smokers
(85 vs. 54 mg/l, pZ 0.05). HNL levels in BAL were positively
correlated with BAL neutrophils (rZ 0.62, p< 0.0001) and
with emphysematous lesions seen on HRCT scan (rZ 0.71,
pZ 0.01)77 (Table 5). Together, the data may indicate HNL
as a candidate marker of neutrophil-mediated lung damage
in cigarette smokers.
Human cationic antimicrobial protein-18 (hCAP-18)
The hCAP-18 is an antimicrobial member of the cathelicidin
family produced by respiratory epithelia and by poly-
morphonuclear leukocytes.168
Induced sputum studies. Xiao and Coworkers showed that
COPD patients had significantly higher levels (75.3 38.9 ng/
mL) of sputum hCAP-18 compared to control non-smoking
subjects (39.9 24.2 ng/mL, p< 0.009). hCAP-18 heavily
stained the cytoplasmic granules of sputum neutrophils,
suggesting that a major source of sputum hCAP-18 was rep-
resented by infiltrating neutrophils. Importantly, hCAP-18
expression showed a strong correlation to the decrease of
airflow, asmeasuredbyFEV1 (%pred).
168 Although these data
may suggest a role for hCAP as a smoke-related inflammation
marker, the lack of an appropriate asymptomatic smoker
control group in the only study published so far, calls for
further confirmatory studies.
Eosinophil cationic protein
The ECP is usually associated with the eosinophil gran-
ulocyte. ECP is a member of the RNase A superfamily of
proteins involved in inflammatory processes mediated by
eosinophils. ECP is bactericidal, helminthotoxic and cyto-
toxic to tracheal epithelium cells as well as to several
mammalian cell lines.169
Induced sputum studies. Rytila and Coworkers showed
that ECP levels in induced sputum of smokers are higher,
although not in a statistically significant fashion, than those
in non-smokers (109 245 vs. 26 20 mg/ml, pZ 0.266).113
This study was largely confirmed by Balzano and
Colleagues, who found higher ECP levels in induced sputum
from patients with COPD (711.5 1,179.9 mg/l) than
asymptomatic smokers (138.8 176.7 mg/l) and non-
smoking controls (81.7 72.3 mg/l) (p< 0.01). In this study,
the difference between healthy smokers and non-smokers
was not statistically significant however, although statis-
tical significance (p< 0.05) was reached for the comparison
between COPD patients and smoking controls. SignificantTable 5 Leukocyte products in induced sputum of tobacco
non-smokers.
Healthy non-smokers Healthy smokers
HNL 54 mg/l 85 mg/la,b
ECP 26 20 mg/ml 109 245 mg/ml
ECP 81.7 72.3 mg/l 138.8 176.7 mg/l
n/a: not available.
a mg/mL of BAL fluid.
b pZ 0.05.correlations were found between FEV1/FVC ratio and
sputum ECP levels (rZ0.56, pZ 0.0126) and between
neutrophil sputum count and ECP concentration (rZ 0.54,
pZ 0.0152).170 The COPD data were confirmed by a study,
evaluating ECP concentrations in BAL samples in smokers
with COPD, which showed that ECP levels were higher in
smokers with COPD than in non-smoking controls.16 In
support to the susceptibility of ECP expression to tobacco
smoke exposure, a study of ECP serum levels by Jensen and
Coworkers showed that ECP concentrations in blood were
more elevated in smokers compared to non-smoker
controls. Strikingly, ECP was linearly associated with daily
cigarette consumption and FEV1. After smoking cessation,
ECP levels decreased within 6 months.171
Together, the data indicate ECP as a marker of inflam-
mation associated with cigarette smoke, although induced
sputum data fail to differentiate healthy smokers from
non-smokers and from smokers with obstructive disease
(Table 5).
Toll-like receptor 2 (TLR2)
Pathogen recognition receptors (PRR) are important
receptors expressed on the macrophage’s cell surface
mediating the interaction between pathogen-associated
molecular patterns (PAMPs) and the cell. Toll-like receptor
4 (TLR4), together with CD14 and the MD2 adapter mole-
cule, serves as receptor for components from Gram-nega-
tive bacteria such as LPS. TLR2 predominantly recognizes
components from Gram-positive bacteria such as lip-
oteichoic acid (LTA) and peptidoglycan (PGN).172
A BAL study by Droemann and Colleagues on macrophage
mRNA and protein expression of TLR2 of COPD patients,
healthy smokers and non-smoking controls showed that the
expression of TLR2 in COPD patients and smokers was
reduced in comparison with non-smokers. Furthermore,
exposure to LPS led to an increased protein and mRNA
expression in non-smokers but not in smoker and COPD
patients macrophages.172 No studies on the TLR2 expression
in induced sputum from smokers are available.
Protease activated receptor 2 (PAR2)
Protease activated receptors (PARs) are members of
the seven transmembrane G-protein-coupled receptor
superfamily. There are 4 known PARs numbered from one
to four, and they are expressed on platelets, endothelial
cells, myocytes and neurons. PARs play an important role
in most components of injury responses, including cell
proliferation, migration, matrix remodelling, and inflam-
mation. PAR2 is preferentially activated by trypsin and




711.5 1179.9 mg/l, p< 0.05 170
Table 6 Summary classification of lung damage
biomarkers associated with tobacco smoke in induced
sputum.
Group Suggested biomarkers
Group.1 GM-CSF, MMP9, MMP-8,
LTB4, 8-isoprostanea
Group.2 GROa, MCP-1, IL-8, NHL,
hCAP18, ECP, a1-ATb
Group.3 CXCL9, CXCL10, CXCL11,
CCL5, NEc
Group.4 SOD, leptin, TGF-ßd
Group.5 TNF-a, VEGF, MPO, EPOe
a Biomarkers of response to tobacco smoke exposure associ-
ated with COPD activity, which are expressed at higher levels in
healthy smokers than in non-smokers and at higher levels in
COPD than in healthy smokers.
b Biomarkers of COPD activity not associated with tobacco
smoke exposure, as their expression is higher in COPD patients
than in controls, with no significant differences between
healthy smokers and non-smokers.
c
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suggest that the expression of PAR genes might be variably
modulated by exposure to tobacco smoke as well as by
inflammation. A study by Miotto and Mapp on tissue biopsies
of the central airways of smokers and non-smokers showed
that PAR2 was expressed in bronchial smooth muscle,
epithelium, glands, and in the endothelium and smooth
muscle of bronchial vessels. PAR2 expression was similar in
the central airways of smokers and non-smokers, but,
among smokers expression was increased in smokers with
symptoms of chronic bronchitis with normal lung function
compared to smokers with both symptoms and airway
obstruction.174
In a BAL study by Roche and Colleagues on cultured
alveolar macrophages, PAR1 mRNA expression was lower in
smokers compared to non-smokers while PAR2 mRNA
expression was higher in smokers. In contrast, no difference
was observed when cultured macrophages were evaluated
for protein expression.175 No studies on PAR1 or PAR2
expression in the LRT of smokers using induced sputum have
been published so far.Biomarkers of response to tobacco smoke exposure not
associated with COPD activity.
d Biomarkers negatively associated with COPD and/or tobacco
smoke exposure.
e Molecules variably associated with COPD and/or tobacco
smoke.Discussion and prospectives
Induced sputum is a non-invasive, standardized sampling
procedure, amenable to diagnosis and monitoring of
patients with inflammatory airways diseases by allowing
access to specific cell types and cell products from the
airways and has been widely used in asthma and COPD
biomarker research.179 Biomarkers can be defined as
molecules which indicate, or are associated with, an
alteration in physiology and may be of clinical utility in
assessing disease activity179: in this context, the paramount
importance of determining the role to active tobacco
smoke in modulating the expression of molecules putatively
amenable to monitoring disease activity and progression in
COPD patients, a disorders strongly associated with tobacco
smoke is apparent. This review summarizes the data
obtained from 16 studies assessing the expression of 19
induced sputum biomarkers in populations of healthy and
COPD affected tobacco smokers and in healthy non-smokers
and the results of 16 studies on the expression of the same
biomarkers in tissue biopsies, bronchoalveolar lavage and
exhaled breath condensate as comparators, as well as the
data and on 20 additional potential biomarkers relevant to
COPD inflammation and tobacco smoke exposure.
For the purpose of this analysis, the respiratory
biomarkers examined could be classified into four groups, in
relation to their association with exposure to tobacco
smoke and/or with COPD (Table 6):
group 1: biomarkers of response to tobacco smoke
exposure, associated with COPD activity, which are
expressed at higher levels in healthy smokers than in
non-smokers and at higher levels in COPD than in healthy
smokers
group 2: biomarkers of COPD inflammation whose
expression level is not associated with tobacco smoke
exposure, as it is higher in COPD patients than in
controls, with no significant differences between
healthy smokers and non-smokersgroup 3: biomarkers of response to tobacco smoke
exposure, not associated with COPD activity
group 4: biomarkers negatively associated with COPD
and/or tobacco smoke exposure
group 5: molecules variably associated with COPD and/
or tobacco smoke
To group 1 can be assigned the cytokine GM-CSF, the
elastolytic protease MMP-9 and the collagenolytic protease
MMP-8. The leukocyte chemo-attractant LTB4 was also
found to overexpressed in COPD compared to smokers, with
BAL studies showing that smokers express higher LTB4 levels
than non-smokers. Similarly, the oxidative stress marker 8-
isoprostane was overexpressed in smokers with moderate-
severe COPD compared to healthy smokers, which in turn
showed higher expression than non-smokers. Similarly,
nitro-peroxidative activity that has been shown to be higher
in COPD than in normal, as nitrotyrosine immunoreactive
cells have been shown in higher percentages in COPD
induced sputum than in normal non-smokers and also in
smokers compared to non-smokers, although no study
directly compared COPD and non-COPD affected smokers.
To group 2 can be assigned the chemokines GRO-a, MCP-
1 and IL-8 and the leukocyte markers NHL, hCAP-18 and ECP
and the antiprotease, the anti-protease a-1-AT, in one
induced sputum study. However, contrary to induced
sputum studies, BAL studies showed that IL-8 levels were
smoke exposure-related. Similarly, a BAL study showed that
a1-AT levels are higher in smokers compared to non-
smokers, albeit in the presence of reduced activity.
To group 3 can be assigned the chemokines CXCL9,
CXCL10, CXCL11, CCL5 and the protease NE. However, no
NE study is available comparing COPD to normal smokers.
1608 A. Comandini et al.To group 4 could be assigned the antioxidant factor SOD,
for it decline in the BAL of smokers, leptin and TGF-b,
although no induced sputum studies are available, to our
knowledge, for theses markers.
Finally, there were molecules variably associated with
COPD and/or tobacco smoke (group 5). Among growth
factors, TNF-a and VEGF have been evaluated with con-
trasting results, as both up-regulation and down-regulation
of their expression were shown in induced sputum and/or
BAL studies. Among oxidative stress related molecules MPO
was associated with smoking history, but no data were
available to analyze the association with COPD and EPO was
associated with COPD, but no sufficient data were available
to assess an association with smoking.
A number of potential COPD biomarkers have not been
examined in induced sputum studies yet. The cytokine IL-1,
although modulated by tobacco smoke exposure in in vitro
studies has not been shown to be consistently associated
either with smoke or with COPD. The cytokines IL-4 and IL-
13 have been associated with tobacco smoking in BAL and
blood studies, the macrophage markers PAR2, TLR2, the
antiprotease factors a-1 AC, SLIPI, a-2-M, associated with
susceptibility to emphysema in genetic studies, the oxida-
tive detoxification and the xenobiotic detoxification
related enzymes of the GST and the Cytochrome P450,
the cytokine-like molecule leptin, the HGF, and TGF-b, the
cytokine the have not been tested, to our knowledge, in
induced sputum studies.
Not unexpectedly, given the differences in the
compartment of the airways and the lung parenchyma
explored by sampling procedures such as induced sputum
and BAL or tissue biopsies, a number of inconsistencies
have emerged which make the characterization of respi-
ratory biomarkers difficult. In addition, most studies eval-
uated small populations thus being unable to reveal
potential dose response effects of tobacco smoke exposure
upon marker expression. In this regard, Vestbo and
coworkers have recently published the design of a large
COPD biomarker study including about 3000 subjects
including COPD patients and both smoking and non-smoking
controls.180
The data summarized in this review suggest that, with
the above caveats, the studies here reviewed suggest that
group 1 and group 2 respiratory biomarkers might be used
as indicators of COPD disease in populations of persons at
risk. Interestingly, group 4 biomarkers might instead be
used to predict disease susceptibility. Studies are needed to
confirm the ability of the biomarkers categorized above to
predict disease severity and response to treatment in COPD
patients, it is though foreseeable that characterization of
COPD markers for their association with tobacco smoke
exposure might be of help in better determine disease
phenotypes.
Finally, it is worth mentioning that the studies described
here have all been carried out following the traditional
approach of laboratory or animal model biomarker studies
i.e., they all focussed on a single gene or protein or on
a few genes/proteins in combination, identified based on
prior knowledge or suspected mechanisms of emphysema/
chronic bronchitis/COPD pathogenesis. As elegantly
pointed out in a recent review of gene association studies
with emphysema risk, newer genetics techniques (e.g.,genome-wide association studies) allow for the compre-
hensive evaluation of the entire genome without prior
assumptions regarding disease biology.176 As genome-wide
studies may lead to the identification of novel disease
candidate genes, to be henceforth subjected to further in
vitro and/or in vivo experimentation, new ‘‘omic’’ tech-
niques such as transcriptomics and proteomics can afford
the investigator with powerful research tools with which to
explore gene expression alterations in the lung exposed to
tobacco smoke.
In this regard, recent gene and protein expression
studies have been carried out using trascriptomics and
proteomics on BAL macrophages and ‘‘brushed’’ bronchial
epithelial cells, although none on induced sputum
samples.177,178 By using of gene chips and proteomic tech-
niques, these studies have led to the identification of
several hundreds of genes/proteins which were modulated
by exposure of tobacco smoke. Interesting, the larger group
of genes and proteins was represented by oxidative stress-
related genes and proteins, a number were related to
apoptosis or cell proliferation and to inflammation/repair.
It is likely that the genome/proteome/metabolome-wide
approaches, coupled with rigorous selection of populations
of homogeneously exposed subjects will greatly improve
upon our ability to identify exposure markers indicative of
tobacco smoke-associated respiratory disease risk.
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